Compare Global Payments Inc (GPN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Global Payments Inc trades at $80.22 (market cap $21.40B), while Vertex Pharmaceuticals Incorporated trades at $483.49 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.7× Global Payments Inc's market cap, and Global Payments Inc pays a 1.28% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| GPN | VRTX | |
|---|---|---|
Market Cap | $21.40B | $121.09B |
Sector | Industrials | Health |
52-Week High | $90.01 | $529.59 |
52-Week Low | $62.47 | $366.54 |
Enterprise Value | $39.11B | $115.83B |
Dividend Yield | 1.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $79.67, up 4.98% today, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust operating cash flow of $2.66B in 2025 and benefits from strategic initiatives like the Worldpay integration and AI-powered POS expansions. However, net income margin turned negative at -7.97% for 2026, reflecting margin pressures amid rising costs and competitive fintech landscape.
GPN presents a mixed outlook: analyst consensus is bullish with a $81.56 price target (58% buy ratings), but investors face risks from debt growth (debt-to-asset ratio rising to 41.57% in 2025) and profitability challenges. Near-term catalysts include continued execution on commerce technology deals, while volatility may persist from macroeconomic headwinds.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
